'For quarter ending June 2024, consolidated Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 6.96% to Rs 814.65 crore compared to quarter ended June 2023. Operating profit margin has jumped from 18.89% to 28.30%, leading to 60.23% rise in operating profit to Rs 230.54 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 19.85% to 16.65%. Purchase of finished goods cost fell from 21.83% to 20.80%. Employee cost decreased from 20.67% to 18.22%. Other expenses fell from 19.63% to 16.57%.
Other income fell 2.20% to Rs 35.64 crore. PBIDT rose 47.62% to Rs 266.18 crore. Provision for interest rose 32.14% to Rs 0.37 crore.
PBDT rose 47.64% to Rs 265.81 crore. Provision for depreciation rose 0.31% to Rs 16.41 crore.
Profit before tax grew 52.37% to Rs 249.40 crore. ...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Revenue up by 3.3% YoY to Rs 4304.7 crore in Q3FY2025
-
-
|
|